CAMP4 Therapeutics Corporation (CAMP)
NASDAQ: CAMPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CAMP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $237.84M
- EPS (TTM)
- -$2.11
- Dividend yield
- None
- 52-week range
- 2.90 – 7.75
- Day range
- 3.78 – 4.00
- Volume / Avg
- 88.48K / 238.88K
- Beta
- —
- Shares outstanding
- 62.75M
52-week range
CAMP stock today
On Nov 20, CAMP ended the session at $3.79, shedding $0.21 (5.25%), versus the S&P 500's 3.70% decline. Trading was light, with 88.48K shares changing hands, about 37% of the average daily volume. Shares are 51.1% below their 52-week high of $7.75, set on Mar 9, 2026 and 30.7% above the 52-week low of $2.90, near the bottom of the past year's range.
CAMP is down 38.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 30.7%. CAMP4 Therapeutics has posted a net loss over the last twelve months (EPS of -$2.11), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About CAMP4 Therapeutics
Company profileCamp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Joshua Mandel-Brehm
- Headquarters
- Watertown, MA
- Employees
- 48
- IPO year
- 2024
- Website
- camp4tx.com
Financial highlights
Full financialsIn fiscal 2025, CAMP4 Therapeutics generated $3.5 million in revenue, up 436.5% from fiscal 2024, its 2nd consecutive year of revenue growth. CAMP4 Therapeutics reported a net loss of $80.4 million, compared with a loss of $51.8 million a year earlier. Operating margin was -1502.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $3.50M | $652.00K | $350.00K |
| Growth | +436.50% | +86.29% | — |
| Net income | $-80.40M | $-51.79M | $-49.29M |
| EPS (diluted) | $-2.65 | $-11.04 | $-124.80 |
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$10.22+169.66%
- Strong buy 3
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.37 vs $-0.20
- Surprise
- -85.00%
CAMP news
All CAMP news- CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European UnionGlobeNewswire
- Raymond James Initiates Coverage of Camp4 Therapeutics with Strong BuyNasdaq
- CAMP4 to Participate in Chardan’s 10th Annual Healthcare ConferenceGlobeNewswire
CAMP4 Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LFCRLifecore Biomedical Inc. | 6.39 | +0.31% | $242.22M | vs CAMP |
| TTRXTurn Therapeutics Inc. | 8.10 | -6.31% | $247.49M | vs CAMP |
| QTTBQ32 Bio Inc. | 8.34 | -1.65% | $249.57M | vs CAMP |
| ENTAEnanta Pharmaceuticals Inc. | 7.62 | -4.51% | $222.19M | vs CAMP |
| IMRXImmuneering Corporation Class A | 3.38 | -2.03% | $218.90M | vs CAMP |
| RCKTRocket Pharmaceuticals Inc. | 1.95 | -7.58% | $217.74M | vs CAMP |
| KROSKeros Therapeutics Inc. | 11.08 | -2.72% | $217.44M | vs CAMP |
| PRLDPrelude Therapeutics Incorporated | 3.23 | -0.77% | $258.63M | vs CAMP |
Indexes, lists and sector
CAMP4 Therapeutics stock FAQ
What is CAMP4 Therapeutics's stock price today?
CAMP last traded at $3.79 as of Nov 20, 4:00 PM EST, down 5.25% on the day. Prices are delayed at least 15 minutes.
Who is CAMP4 Therapeutics's CEO?
Mr. Joshua Mandel-Brehm is the chief executive officer of CAMP4 Therapeutics Corporation, which has about 48 employees.
What is the CAMP 52-week high?
The 52-week high for CAMP is $7.75 and the 52-week low is $2.90. The stock is currently 51.1% below its high.